Select Equity Group L.P. Has $43.62 Million Holdings in Danaher Corporation $DHR

Key Points

• Select Equity Group L.P. increased its holdings in Danaher Corporation by 37.9% during Q1, totaling 212,766 shares worth approximately $43.6 million.
• Danaher reported Q2 earnings of $1.80 per share, exceeding expectations and showing a year-over-year revenue increase of 3.4% to $5.94 billion.
• Analysts have mixed views on Danaher's stock, with price targets ranging from $205.00 to $275.00 and the current average rating being a "Moderate Buy."

Select Equity Group L.P. grew its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 37.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 212,766 shares of the conglomerate's stock after acquiring an additional 58,485 shares during the quarter. Select Equity Group L.P.'s holdings in Danaher were worth $43,617,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Hills Bank & Trust Co boosted its position in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after acquiring an additional 53 shares during the period. Sageworth Trust Co boosted its position in shares of Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after acquiring an additional 54 shares during the period. 1834 Investment Advisors Co. boosted its position in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 54 shares during the period. Rakuten Securities Inc. boosted its position in shares of Danaher by 33.3% in the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after acquiring an additional 56 shares during the period. Finally, Kingswood Wealth Advisors LLC boosted its position in shares of Danaher by 1.6% in the first quarter. Kingswood Wealth Advisors LLC now owns 3,466 shares of the conglomerate's stock valued at $710,000 after acquiring an additional 56 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DHR shares. Barclays reissued an "overweight" rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Guggenheim reaffirmed a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Evercore ISI cut their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Trading Down 2.2%

Shares of Danaher stock traded down $4.39 on Tuesday, hitting $194.24. The stock had a trading volume of 3,344,891 shares, compared to its average volume of 2,899,976. The stock has a 50 day moving average of $201.82 and a 200 day moving average of $199.20. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market capitalization of $139.09 billion, a P/E ratio of 41.33, a PEG ratio of 2.77 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the firm posted $1.72 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.